Ewing sarcoma is a malignant type of bone tumor, meaning it is a form of cancer that spreads. According to a 2024 review, Ewing sarcoma is the second most common primary cancerous bone tumor. It ...
Inhibrx Biosciences, Inc. stays a Strong Buy with Q2 2026 ozekibart BLA catalyst, 2026 PFS data, and Ewing sarcoma updates.
Kimberley Nix was a 28-year-old medical resident when she was diagnosed with metastatic sarcoma. Today, she continues her studies while sharing her journey on social media Stephanie Sengwe is a pop ...
Detailed price information for Actuate Therapeutics Inc (ACTU-Q) from The Globe and Mail including charting and trades.
Canada-based influencer Dr Kimberly Nix has died three years after being diagnosed with metastatic sarcoma. Dr Nix was known for documenting her journey with cancer on Instagram and TikTok. Her final ...
Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System Patients treated on regimen B did not have significantly better ...
Neoadjuvant treatment evaluation in soft tissue sarcomas (STS): Looking for news in radiologic and pathologic response. Background: Uterine leiomyosarcoma (LMS) is a rare disease and, when recurs or ...
Combination therapy of botensilimab (BOT) plus balstilimab (BAL) was approved Monday as an updated national treatment protocol for patients with certain ovarian cancers and soft tissue sarcomas (STS) ...
Soft tissue sarcomas rarely metastasize to the heart, with cardiac involvement seen in less than 0.03% of cases. Metastatic heart disease presents diagnostic challenges due to nonspecific symptoms, ...
SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and ...
Kimberly Nix was well into her journey to become a doctor when life threw a wrench at her: She was diagnosed with metastatic sarcoma in 2021. At the time, Dr. Nix was only 28 years old and in the ...